The C3i Innovation and Commercialization Unit is led by industry experienced professionals with the mission to identify and accelerate the development of innovative technologies in immuno-oncology. It essentially relates to the experience and expertise and its personnel toward achieving C3i’s business goals and objectives.
Our advantage lies in our ability to leverage the capabilities of the existing and operational Biomarkers and Diagnostic, Clinical Research and GMP manufacturing Units within Maisonneuve-Rosemont Hospital to step in and address the needs of potential companies.
C3i can participate as an investment partner with other financial institutions such as venture capital and biotechnology partners, with direct cash investments as well as leveraging services as in-kind contributions in exchange for equity.
Our vision is to be Canada’s catalyst for the business development of cancer immunotherapy with the goal to become a world center of expertise participating in the ultimate battle against cancer.